PT3612237T - Terapia genética - Google Patents
Terapia genéticaInfo
- Publication number
- PT3612237T PT3612237T PT187195441T PT18719544T PT3612237T PT 3612237 T PT3612237 T PT 3612237T PT 187195441 T PT187195441 T PT 187195441T PT 18719544 T PT18719544 T PT 18719544T PT 3612237 T PT3612237 T PT 3612237T
- Authority
- PT
- Portugal
- Prior art keywords
- gene therapy
- therapy
- gene
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706394.2A GB201706394D0 (en) | 2017-04-21 | 2017-04-21 | Gene Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3612237T true PT3612237T (pt) | 2021-12-02 |
Family
ID=58795636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT187195441T PT3612237T (pt) | 2017-04-21 | 2018-04-20 | Terapia genética |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11964027B2 (enExample) |
| EP (2) | EP3612237B1 (enExample) |
| JP (2) | JP7443063B2 (enExample) |
| CN (1) | CN110769860B (enExample) |
| AU (1) | AU2018253958B2 (enExample) |
| CA (1) | CA3060128A1 (enExample) |
| DK (1) | DK3612237T3 (enExample) |
| ES (1) | ES2900560T3 (enExample) |
| GB (1) | GB201706394D0 (enExample) |
| HR (1) | HRP20211803T1 (enExample) |
| HU (1) | HUE056570T2 (enExample) |
| IL (1) | IL270032B2 (enExample) |
| LT (1) | LT3612237T (enExample) |
| PL (1) | PL3612237T3 (enExample) |
| PT (1) | PT3612237T (enExample) |
| RS (1) | RS62619B1 (enExample) |
| SI (1) | SI3612237T1 (enExample) |
| WO (1) | WO2018193118A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850484C (en) * | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| WO2023077107A1 (en) * | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202208550D0 (en) * | 2022-06-10 | 2022-07-27 | Ospedale San Raffaele Srl | Cyclosporin h and uses thereof |
| GB202209098D0 (en) * | 2022-06-21 | 2022-08-10 | Ucl Business Ltd | Cyclosporine analogues |
| JP2025530652A (ja) | 2022-08-11 | 2025-09-17 | フォンダジオン テレソン イーティーエス | 遺伝子治療 |
| EP4602153A1 (en) | 2022-10-11 | 2025-08-20 | Fondazione Telethon ETS | 3d cell culture methods |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| IT202300022191A1 (it) | 2023-10-24 | 2025-04-24 | Fond Telethon Ets | Mezzi e metodi per la modifica genetica di uba1 |
| EP4640830A1 (en) | 2024-04-23 | 2025-10-29 | Fondazione Telethon ETS | Means and methods for safe and efficient gene editing in cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| CZ297278B6 (cs) | 1996-08-07 | 2006-10-11 | Darwin Discovery Limited | Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| JP2006513153A (ja) | 2002-10-09 | 2006-04-20 | ロランティス リミテッド | 免疫機能の調節 |
| DE602004030105D1 (de) * | 2003-05-05 | 2010-12-30 | Virxsys Corp | Erhöhte transduktion mit abc-transportersubstratenhemmern |
| US9669049B2 (en) | 2010-10-31 | 2017-06-06 | Tocagen Inc. | Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders |
| WO2014109728A1 (en) | 2013-01-11 | 2014-07-17 | The Scripps Research Institute | Methods and compositions for enchancing transduction efficiency of retroviral vectors |
| ES2747951T3 (es) | 2013-10-24 | 2020-03-12 | Ospedale San Raffaele Srl | Método |
| GB201407322D0 (en) * | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
-
2017
- 2017-04-21 GB GBGB1706394.2A patent/GB201706394D0/en not_active Ceased
-
2018
- 2018-04-20 PL PL18719544T patent/PL3612237T3/pl unknown
- 2018-04-20 JP JP2019556865A patent/JP7443063B2/ja active Active
- 2018-04-20 ES ES18719544T patent/ES2900560T3/es active Active
- 2018-04-20 PT PT187195441T patent/PT3612237T/pt unknown
- 2018-04-20 HU HUE18719544A patent/HUE056570T2/hu unknown
- 2018-04-20 EP EP18719544.1A patent/EP3612237B1/en active Active
- 2018-04-20 US US16/606,633 patent/US11964027B2/en active Active
- 2018-04-20 WO PCT/EP2018/060237 patent/WO2018193118A1/en not_active Ceased
- 2018-04-20 RS RS20211471A patent/RS62619B1/sr unknown
- 2018-04-20 DK DK18719544.1T patent/DK3612237T3/da active
- 2018-04-20 AU AU2018253958A patent/AU2018253958B2/en active Active
- 2018-04-20 SI SI201830485T patent/SI3612237T1/sl unknown
- 2018-04-20 LT LTEPPCT/EP2018/060237T patent/LT3612237T/lt unknown
- 2018-04-20 CN CN201880038804.7A patent/CN110769860B/zh active Active
- 2018-04-20 CA CA3060128A patent/CA3060128A1/en active Pending
- 2018-04-20 IL IL270032A patent/IL270032B2/en unknown
- 2018-04-20 EP EP21194123.2A patent/EP3973996A1/en active Pending
- 2018-04-20 HR HRP20211803TT patent/HRP20211803T1/hr unknown
-
2023
- 2023-12-26 JP JP2023219262A patent/JP2024045128A/ja active Pending
-
2024
- 2024-03-06 US US18/597,488 patent/US12485187B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018193118A1 (en) | 2018-10-25 |
| US12485187B2 (en) | 2025-12-02 |
| CA3060128A1 (en) | 2018-10-25 |
| US20210121579A1 (en) | 2021-04-29 |
| JP2024045128A (ja) | 2024-04-02 |
| CN110769860A (zh) | 2020-02-07 |
| JP2020517253A (ja) | 2020-06-18 |
| EP3612237A1 (en) | 2020-02-26 |
| RS62619B1 (sr) | 2021-12-31 |
| HRP20211803T1 (hr) | 2022-03-04 |
| HUE056570T2 (hu) | 2022-02-28 |
| LT3612237T (lt) | 2022-01-25 |
| AU2018253958B2 (en) | 2024-03-07 |
| IL270032A (enExample) | 2019-12-31 |
| DK3612237T3 (da) | 2021-12-06 |
| EP3612237B1 (en) | 2021-09-01 |
| ES2900560T3 (es) | 2022-03-17 |
| SI3612237T1 (sl) | 2022-02-28 |
| EP3973996A1 (en) | 2022-03-30 |
| GB201706394D0 (en) | 2017-06-07 |
| IL270032B1 (en) | 2024-11-01 |
| IL270032B2 (en) | 2025-03-01 |
| CN110769860B (zh) | 2024-03-08 |
| US20240350661A1 (en) | 2024-10-24 |
| PL3612237T3 (pl) | 2022-02-14 |
| US11964027B2 (en) | 2024-04-23 |
| JP7443063B2 (ja) | 2024-03-05 |
| AU2018253958A1 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202400506T1 (it) | Terapia genica | |
| MA47680A (fr) | Arn thérapeutique | |
| DK3262066T4 (da) | Genterapi | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| EP3551285C0 (en) | DEFIBRILLATOR | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| DK3433368T3 (da) | Transreplikerende rna | |
| HRP20190165T1 (hr) | Genska terapija za fabryjevu bolest | |
| EP3291824A4 (en) | ANTIMICROBIAL THERAPY | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| IL272373A (en) | Factor viii (fviii) gene therapy methods | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| SI3612237T1 (sl) | Genska terapija | |
| EP3717652A4 (en) | GENE THERAPY FOR MUCOPOLY SACCHARIDOSIS IIIB | |
| EP3413927A4 (en) | CANCER THERAPY | |
| KR20180084747A (ko) | Galgt2 유전자 치료 방법 및 물질 | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3393478T3 (da) | Kombinationsterapi | |
| IL262851A (en) | Combination prime: boost therapy | |
| EP3619311C0 (en) | DNA ASSEMBLY | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| EP3518957C0 (en) | Therapeutic protein | |
| LT3324951T (lt) | Peritoninis terapinis skystis | |
| GB201701968D0 (en) | Gene therapy |